Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3385 Velaglucerase alfa

J Codes (Drugs)

Also known as: velaglucerase alfa, VPRIV, enzyme replacement therapy

Velaglucerase alfa injection is a recombinant enzyme replacement therapy used for Gaucher disease Type 1 treatment.

In Plain Language

genetic storage disease treatment; enzyme replacement infusion

Clinical Context

Used in Gaucher disease Type 1 for enzyme replacement therapy. Recombinant glucocerebrosidase that reduces hepatosplenomegaly and hematologic abnormalities. Administered intravenously every 2 weeks.

RVU Information

CPT J3385 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

Hematology/OncologyRare Disease SpecialistsGenetic Medicine

Frequently Asked Questions

What is CPT code J3385?

CPT J3385 (Velaglucerase alfa) is a J Codes (Drugs) code. Velaglucerase alfa injection is a recombinant enzyme replacement therapy used for Gaucher disease Type 1 treatment.

How is J3385 administered?

CPT J3385 is administered by a healthcare provider, typically via injection or infusion. Used in Gaucher disease Type 1 for enzyme replacement therapy. Recombinant glucocerebrosidase that reduces hepatosplenomegaly and hematologic abnormalities. Administered intravenously every 2 weeks. It is used by Hematology/Oncology, Rare Disease Specialists, Genetic Medicine.

When is CPT J3385 used?

Used in Gaucher disease Type 1 for enzyme replacement therapy. Recombinant glucocerebrosidase that reduces hepatosplenomegaly and hematologic abnormalities. Administered intravenously every 2 weeks.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.